Navigation Links
IRSF announces 2013 awards and implements new Translational Program
Date:2/24/2014

Cincinnati, (OH) The International Rett Syndrome Foundation (IRSF) announces today ten (10) new research grants at leading global research institutions; a new Translational Research Program; and additional funding for current human clinical trials.

The funding awarded in 2013 covers the spectrum of Rett syndrome research, from basic discovery starting at the genetic level all the way to treating the girls diagnosed with Rett syndrome. Awards are not restricted by geographic boundaries, and several of the new IRSF grants are invested in researchers from Canada and Australia. IRSF remains steadfast in recruiting talented young scientists to the research bench for Rett syndrome, and welcomes three new IRSF fellows into the IRSF training fellowship program.

In an effort to move potential therapeutics past the translational research funding gap and into clinics, IRSF announces the Scout Program, a Drug Discovery Screen in a mouse model of Rett syndrome that will aggressively accelerate the testing of compounds, whether new or repurposed, through standardized preclinical studies. The Scout Program was created to replicate and confirm encouraging results stemming from studies performed in academic labs as well as testing of compounds no labs are pursuing. The Contract Research Organization (CRO) PsychoGenics, Inc. in Tarrytown, NY is the testing bed for this program and will independently test selected drugs using the set standards in preclinical studies for Rett syndrome. Outcomes from this program will provide the complementary high quality data required to move promising compounds through federal review and along the drug development pipeline toward the clinic.

"IRSF is taking the next logical step forward in developing programs that move the basic science discovery findings forward to rigorist pre-clinical trials. This is in concert with recent announcements and publications coming out of the National Institutes of Health for more rigor and replication of reported science before moving forward to clinical trials," said Steven Kaminsky, PhD, the Chief Science Officer of IRSF.

Rajat Shah, Chairman of the IRSF Board of Directors adds, "The Board is excited about the research direction that IRSF is taking. Accelerating the pace at which new drugs will move towards human clinical trials while identifying areas of research that need to be filled is of utmost importance to IRSF. Our sincerest thanks to all our families, donors, and supporters who have helped us fund this compelling research."

New Translational Research Awards

  • Theresa E. Bartolotta, PhD, Seton Hall University and Patricia Remshifski, PhD, Monmouth University

    Eyetracking in Rett syndrome: A preliminary investigation of receptive and expressive vocabulary

  • John Christodoulou, AM, Sydney Children's Hospital Network, Australia

    Preclinical Evaluation of Tubastatin A, a Novel Therapy for Rett Syndrome

  • Steven Gray, PhD, University of North Carolina at Chapel Hill

    BDNF gene transfer for the treatment of RTT

  • Jeannie Lee, MD, Ph.D, Massachusetts General Hospital

    Treating Rett syndrome via selective reactivation of the silenced MECP2 allele

New Basic Research Awards-Regular Research Grants

  • Kerry Delaney, PhD, University of Victoria, Canada

    In vivo imaging of spine turnover rates in the heterozygous female Rett mouse brain

  • Xinyu Zhao, PhD, University of Wisconsin-Madison

    Restoring network integration of MeCP2-deficient neurons

  • Serena M. Dudek, PhD, National Institute of Environmental Health Sciences

    Role of IGF1R in hippocampal CA2 plasticity and function: interaction with MeCP2

New Mentored Training Fellowships

  • Farshad Moradpour, PhD, University of Victoria, Canada

    Neurophysiology of cortical neurons in heterozygous female Rett mouse brain

  • Deivid Rodrigues, PhD, The Hospital For Sick Children, Canada

    Post-transcriptional control of MECP2 expression during human development and disease

  • Rocco George Gogliotti, PhD, Vanderbilt University Medical Center

    Temporal divergence of hypoconnectivity and excitotoxicity in Rett syndrome

New IRSF Scout Program

  • Daniela Brunner, PhD, PyschoGenics, Inc.

    A Drug Discovery Screen in a Mouse Model of Rett Syndrome

Supplemental Funding for Current ANGEL Awards

  • Walter Kaufmann, MD, Boston Children's Hospital

    A Phase 2b placebo-controlled cross-over study of rh-IGF1 (mecasermin [DNA] injection) for treatment of Rett syndrome and development of Rett-specific novel biomarkers of cortical and autonomic function

  • Daniel Glaze, MD, Baylor College of Medicine

    A randomized, double-blind placebo controlled trial of NNZ-2566 (IGF-1{1-3}, glycyl-L-2-methylprolyl-L-glutamine acid) with open label extension in adults with Rett syndrome


'/>"/>
Contact: Steven Kaminsky
skaminsky@rettsyndrome.org
International Rett Syndrome Foundation
Source:Eurekalert

Related biology news :

1. Modern Mobility Aids, Inc. Announces a Revised Agreement for the Acquisition of Lumigene
2. ChromaDex® Announces Financial Results for the Year Ended 2011
3. Improved Authentication and Confidentiality Protection. ICAP Patent Brokerage Announces for Auction Important Patents in Data Encryption and Document Security
4. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
5. Global Information Inc. Announces Discounted Conference Registration For Bio-IT World Asia and Biodetection Technologies 2012
6. Virginia Tech announces 2012 football helmet ratings; 2 more added to the 5-star mark
7. Medbox, Inc. Announces Top-Tier Rating by Dun & Bradstreet Credibility Corporation
8. BioLife Solutions Announces 7th Consecutive Quarter of Record Revenue
9. Mass. Eye and Ear announces Curing Kids Fund grant recipients
10. Bay Area PV Consortium announces $7.5 million in grants to lower the cost of large-scale solar
11. BioMed Central announces winners of 6th Annual Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017 MedNet ... that supports the entire spectrum of clinical research, ... another record-breaking year for the organization in terms ... in MedNet,s eClinical products and services. The company,s ... marketplace success of iMedNet ...
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology market is ... 19.4% from 2016 to 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017  An international ... of Medicine and St. Boniface Hospital Albrechtsen Research ... peripheral neuropathy, an unmet health need affecting nearly ... Journal of Clinical Investigation, their results identify small ... prevent and reverse neuronal injury in animal models ...
(Date:1/17/2017)... LEXINGTON, Mass. , Jan. 17, 2017   ... clinical stage biopharmaceutical company developing innovative inhaled therapies to ... candidate for treating fungal infections in the lungs of ... Infectious Disease Product" (QIDP) by the U.S. Food & ... , which is designed to speed the development of ...
(Date:1/17/2017)... 17, 2017  Only nine percent of U.S. consumers ... while only 16 percent believe health insurance companies do, ... 36 percent of U.S. adults believe health care providers ... compared to hospitals (23%). "We are in ... Wendy Salomon , vice president of reputation management and ...
(Date:1/17/2017)... ... January 17, 2017 , ... Pono Ola , a mind-body wellness firm ... today the official launch of its much-anticipated Pono Board: a re-invented fitness and anti-fatigue ... development for over a year, the patented Pono Board is the world’s only exercise ...
Breaking Biology Technology: